| 2025-12-22 |
详情>>
内部人交易：
Hohl Benjamin股份增加13000.00股
|
| 2025-11-12 |
详情>>
股本变动：
变动后总股本5934.73万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.35美元,归母净利润-7402.7万美元,同比去年增长-12.43%
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-1.05美元,归母净利润-5387.9万美元,同比去年增长-26.22%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.57美元,归母净利润-2854.4万美元,同比去年增长-25.53%
|
| 2025-04-28 |
股东大会：
将于2025-06-24召开股东大会
会议内容 ▼▲
- 1.To elect the three Class II directors named in the accompanying proxy statement to serve until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025.
3.To transact other business that may properly come before the Annual Meeting.
|
| 2025-03-13 |
详情>>
业绩披露：
2024年年报每股收益-1.89美元,归母净利润-8902.4万美元,同比去年增长-24.36%
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.43美元,归母净利润-6584.4万美元,同比去年增长-26.1%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.95美元,归母净利润-4268.8万美元,同比去年增长-35.75%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.54美元,归母净利润-2273.8万美元,同比去年增长-54.43%
|
| 2024-04-26 |
股东大会：
将于2024-06-18召开股东大会
会议内容 ▼▲
- 1.To elect the two Class I directors named in the accompanying proxy statement to serve until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal year ending December 31, 2024.
3.To approve an amendment to our restated certificate of incorporation to limit the liability of certain officers as permitted by Delaware law.
4.To approve the amendment and restatement of the Amended and Restated 2020 Equity Incentive Plan (the “Equity Plan”), which increases the number of shares authorized for issuance thereunder by 2,900,000 shares.
5.To transact other business that may properly come before the Annual Meeting.
|
| 2024-03-14 |
详情>>
业绩披露：
2023年年报每股收益-2.01美元,归母净利润-7158.4万美元,同比去年增长-90.07%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.55美元,归母净利润-5221.4万美元,同比去年增长-85.74%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-1.05美元,归母净利润-3144.5万美元,同比去年增长-79.09%
|
| 2023-04-28 |
股东大会：
将于2023-06-23召开股东大会
会议内容 ▼▲
- 1.To elect the two Class III directors named in the accompanying proxy statement to serve until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal year ending December 31, 2023.
3.To transact other business that may properly come before the Annual Meeting.
|
| 2023-02-22 |
复牌提示：
2023-02-22 09:31:01 停牌，复牌日期 2023-02-22 09:41:01
|
| 2023-02-22 |
详情>>
拆分方案：
每4.0000合并分成1.0000股
|
| 2022-10-07 |
股东大会：
将于2022-11-09召开股东大会
会议内容 ▼▲
- 1.To approve the sale (the “asset sale”) by Imara to Cardurion Pharmaceuticals, Inc. (“Cardurion” or the “Buyer”) of tovinontrine (IMR-687) and all other assets of Imara related to its PDE9 program, pursuant to the terms of the related Asset Purchase Agreement, dated September 6, 2022 (the “asset purchase agreement”), for an upfront cash payment of $34,750,000 upon closing of the asset sale (in addition to $250,000 previously paid by Cardurion to Imara upon execution of a non-binding term sheet), a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the asset purchase agreement and subject to the terms and conditions of the asset purchase agreement (the “Asset Sale Proposal”);
2.To approve the adjournment of the Special Meeting, if necessary and to the extent permitted by the asset purchase agreement, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Asset Sale Proposal (the “Adjournment Proposal”).
|
| 2022-04-22 |
股东大会：
将于2022-06-02召开股东大会
会议内容 ▼▲
- 1.Election of two class II directors, Rahul D. Ballal, Ph.D. and Barbara J. Dalton, Ph.D., nominated by our board of directors, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders;
2.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; 3.Transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-05-18 |
股东大会：
将于2021-06-29召开股东大会
会议内容 ▼▲
- 1.Election of three class I directors, Edward R. Conner, M.D., Carl Goldfischer, M.D. and Laura Williams, M.D., MPH, nominated by our board of directors, each to serve for a three-year term expiring at the 2024 annual meeting of stockholders;
2.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; 3.Transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|